E-ethyl 3-azidoacrylate | 116270-20-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: E-ethyl 3-azidoacrylate
• 英文别名: ethyl 3-azidopropenoate；Ethyl 3-azidoacrylate；ethyl (E)-3-azidoprop-2-enoate
• CAS: 116270-20-3
• 化学式: C₅H₇N₃O₂
• 分子量: 141.129
• InChiKey: TVHAQPLDXOTSQI-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  40.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  E-ethyl 3-azidoacrylate 以 二氯甲烷 为溶剂， 生成 1,4-Bis(ethoxycarbonyl)-2-azabuta-1,3-diene
  参考文献：
  名称：

  Preparation and reactivity of electron-poor 2-azadienes. Diels-Alder reaction with trans-cyclooctene.

  摘要：

  Di-, tri- and tetra- substituted 2-azadienes 3 underbar with electron withdrawing groups have been obtained by Aza-Wittig reaction of N-vinylic phosphazenes with carbonyl compounds. The Diels-Alder reaction of 3 underbar with trans-cyclooctene has also been explored.

  DOI：

  10.1016/s0040-4039(00)79357-9
• 作为产物：
  描述：

  丙炔酸乙酯 在 Sodium tetraborate decahydrate 、 potassium dihydrogenphosphate 、 sodium azide 作用下， 以 水 为溶剂， 反应 3.0h， 生成 Z-ethyl 3-azidoacrylate 、 E-ethyl 3-azidoacrylate
  参考文献：
  名称：

  Priebe, Hanno, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1987, vol. 41, # 9, p. 640 - 645

  摘要：

  DOI：

文献信息

• Priebe, Hanno, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1987, vol. 41, # 9, p. 640 - 645
  作者：Priebe, Hanno

  DOI：——

  日期：——
• Synthesis and Reactivity of Electron-Poor 2-Azadienes. [4 + 2] Cycloaddition Reactions with Alkenes and Enamines
  作者：Francisco Palacios、Itziar Perez de Heredia、Gloria Rubiales

  DOI：10.1021/jo00113a017

  日期：1995.4

  Electron deficient 2-azadienes derived from beta-amino acids 3 are obtained by aza-Wittig reaction of N-vinylic phosphazenes 4 with carbonyl compounds. Inverse electron demand Diels-Alder reaction of azadienes 3 with trans-cyclooctene 7 and cis,trans-cyclooctadiene 8 leads to the formation of trans-cycloalkanotetrahydropyridines 10. Heterodienes 3 also react with enamines 13, 14, and 18 affording pyridine derivatives 16, 17, and 20 in a regioselective fashion. Norbornadiene 11, a less strained olefin than cycloalkenes 7 and 8, requires the presence of lithium perchlorate as catalyst in a nonaqueous solvent like ether, to give cycloadducts 12.
• Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents
  作者：Kasa Shiva Raju、Sandeep AnkiReddy、Gowravaram Sabitha、Vagolu Siva Krishna、Dharmarajan Sriram、Kunduru Bharathi Reddy、Someswar Rao Sagurthi

  DOI：10.1016/j.bmcl.2018.11.036

  日期：2019.1

  A series of novel 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives have been synthesized in good to excellent yields. Through the copper-catalyzed azide-alkyne cycloaddition via reaction of 7-(prop-2-ynyl)-7H-pyrrolo[2,3-d]pyrimidine and aryl, heteroaryl and alkyl azides in the presence of CuSO4 center dot 5H(2)O and sodium ascorbate. These compounds were evaluated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv strain. Most of these pyrrolopyrimidine-triazole hybrids exhibited good anti tubercular activity. The antimycobacterial assay results showed that the minimum inhibitory concentration of compounds 4q and 4r were 0.78 mu g/mL. The molecular docking results also had shown highest Moldock score for same compounds. These novel compounds exhibited good inhibition activities and further structure-activity studies of the derivatives had shown promising features to use in antitubercular therapy.
• PRIEBE, HANNO, ACTA CHEM. SCAND., 41,(1987) N 9, 640-645
  作者：PRIEBE, HANNO

  DOI：——

  日期：——
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：[en]VENTUS THERAPEUTICS U.S., INC.

  公开号：WO2023081441A1

  公开（公告）日：2023-05-11

  The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, labeled isotopes, or tautomers thereof, in the treatment of cGAS-related diseases and disorders.